{"id":2684,"date":"2025-10-27T13:15:16","date_gmt":"2025-10-27T13:15:16","guid":{"rendered":"https:\/\/network.rvrising.com\/?p=2684"},"modified":"2025-10-27T13:15:16","modified_gmt":"2025-10-27T13:15:16","slug":"moonlake-immunotherapeutics-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.rvrising.com\/news\/business\/moonlake-immunotherapeutics-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/","title":{"rendered":"MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"},"content":{"rendered":"

SAN DIEGO<\/span>, Oct. 27, 2025<\/span> \/PRNewswire\/ — Robbins Geller Rudman & Dowd LLP<\/a><\/b> announces that the MoonLake <\/i>class action lawsuit \u2013 captioned Peters v. MoonLake Immunotherapeutics<\/i>, No. 25-cv-08612, and pending in the Southern District of New York \u2013 seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX<\/a>) common stock and charges MoonLake as well as certain of MoonLake’s top executives with violations of the Securities Exchange Act of 1934.<\/p>\n

\n

If you suffered substantial losses and wish to serve as lead plaintiff of the MoonLake <\/i>class action lawsuit, please provide your information here:<\/b><\/p>\n

https:\/\/www.rgrdlaw.com\/cases-moonlake-immunotherapeutics-class-action-lawsuit-mltx.html<\/a> <\/b><\/p>\n

You can also contact attorneys J.C. Sanchez<\/a> or Jennifer N. Caringal<\/a> of Robbins Geller by calling 800\/449-4900 or via e-mail at [email\u00a0protected]<\/span><\/a>. Lead plaintiff motions for the\u00a0MoonLake <\/i>class action lawsuit must be filed with the court no later than December 15, 2025.<\/b><\/p>\n

CASE ALLEGATIONS<\/b>: MoonLake is a clinical stage biotechnology company that focuses on developing therapies for inflammatory skin and joint diseases. According to the complaint,\u00a0MoonLake’s sole drug candidate is sonelokimab (“SLK”), which was developed primarily for the treatment of hidradenitis suppurativa (“HS”). Central to\u00a0SLK’s commercial prospects was its ability to demonstrate efficacy in HS comparable or superior to Union Chimique Belge’s BIMZELX, a U.S. Food & Drug Administration-approved monoclonal antibody for the same indication, the complaint alleges.<\/p>\n

The MoonLake <\/i>class action lawsuit alleges that defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (i) SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (ii) SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; and (iii) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy.<\/p>\n

The MoonLake<\/i> class action lawsuit alleges that on September 28, 2025, MoonLake announced 16-week results from its Phase 3 VELA program which showed that SLK failed to demonstrate competitive efficacy relative to BIMZELX. On this news, the price of MoonLake stock fell nearly 90%, according to the complaint.<\/p>\n

THE LEAD PLAINTIFF PROCESS<\/b>: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired MoonLake common stock during the class period to seek appointment as lead plaintiff in the MoonLake <\/i>class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the MoonLake <\/i>class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the MoonLake <\/i>class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the MoonLake <\/i>class action lawsuit.<\/p>\n

ABOUT ROBBINS GELLER<\/b>: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases \u2013 more than the next five law firms combined, according to ISS. With 200 attorneys in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever \u2013 $7.2 billion \u2013 in In re Enron Corp. Sec. Litig.<\/i> Please visit the following page for more information:<\/p>\n

https:\/\/www.rgrdlaw.com\/services-litigation-securities-fraud.html<\/a> <\/b><\/p>\n

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.<\/p>\n

Contact:<\/p>\n

Robbins\u00a0Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email\u00a0protected]<\/span><\/a><\/b><\/p>\n

SOURCE Robbins Geller Rudman & Dowd LLP<\/p>\n<\/div>\n

This release is auto-published via PR Newswire; our journal is not responsible for the content.<\/b><\/p>\n

Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, Oct. 27, 2025 \/PRNewswire\/ — Robbins Geller Rudman & Dowd LLP announces that the MoonLake class<\/p>\n","protected":false},"author":1,"featured_media":2685,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,92],"tags":[223],"class_list":["post-2684","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-pr-newswire","tag-robbins-geller-rudman-dowd-llp"],"_links":{"self":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/2684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/comments?post=2684"}],"version-history":[{"count":1,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/2684\/revisions"}],"predecessor-version":[{"id":2699,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/2684\/revisions\/2699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media\/2685"}],"wp:attachment":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media?parent=2684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/categories?post=2684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/tags?post=2684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}